
    
      Each patient will participate for up to 52 weeks, which includes a Screening Period, followed
      by a Baseline Visit and open-label treatment for 1 year with a safety Follow-up 4 weeks after
      the last treatment.

        -  Screening Period: up to 6 weeks.

        -  Open-Label Treatment Period: 52 weeks (1 year)

        -  Post-Treatment Safety Follow Up: 4 weeks.
    
  